Access to anti-retroviral drugs, female in Egypt

Egypt: Access to anti-retroviral drugs, female was 46.0% in 2024. ◆ Volatile

Latest (2024)
46.0%
Change on year
up 17.9%
World rank
125th
of 141 countries
All-time high
46.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Egypt, 2000–2024

010203040502000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 0 %2005: 0 %2006: 0 %2007: 0 %2008: 0 %2009: 1 %2010: 3 %2011: 4 %2012: 5 %2013: 7 %2014: 10 %2015: 12 %2016: 16 %2017: 23 %2018: 30 %2019: 30 %2020: 30 %2021: 33 %2022: 36 %2023: 39 %2024: 46 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, female in Egypt stood at 46.0%. That is the highest value across all 25 years on record.

That represents a change of up 17.9% on the previous year and up 360.0% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Egypt peaked at 46.0% in 2024 and was at its lowest, 0.0%, in 2000.

Egypt ranks 125th of 141 countries on this measure, in the bottom quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Egypt, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Egypt, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 0.0%
2005 0.0%
2006 0.0%
2007 0.0%
2008 0.0%
2009 1.0%
2010 3.0% +200.0%
2011 4.0% +33.3%
2012 5.0% +25.0%
2013 7.0% +40.0%
2014 10.0% +42.9%
2015 12.0% +20.0%
2016 16.0% +33.3%
2017 23.0% +43.8%
2018 30.0% +30.4%
2019 30.0% +0.0%
2020 30.0% +0.0%
2021 33.0% +10.0%
2022 36.0% +9.1%
2023 39.0% +8.3%
2024 46.0% +17.9%

Averages by decade

DecadeAverage LowestHighest Years
2000s 0.1% 0.0% 1.0% 10
2010s 14.0% 3.0% 30.0% 10
2020s 36.8% 30.0% 46.0% 5

Countries ranked near Egypt

  1. 122 Angola 50.0% compare
  2. 123 North Macedonia 49.0% compare
  3. 124 Malta 47.0% compare
  4. 126 Qatar 43.0% compare
  5. 127 Syrian Arab Republic 41.0% compare
  6. 128 Madagascar 39.0% compare

See the full ranking of 160 places →

More gender data for Egypt

All data for Egypt →

Frequently asked questions

What is access to anti-retroviral drugs, female in Egypt?
Access to anti-retroviral drugs, female in Egypt was 46.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Egypt?
The highest recorded value was 46.0% in 2024.
What is the lowest access to anti-retroviral drugs, female recorded in Egypt?
The lowest recorded value was 0.0% in 2000.
How does Egypt rank for access to anti-retroviral drugs, female?
Egypt ranks 125th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Egypt?
Over the last ten years it is up 360.0%. The long-run trend across the full record is volatile.
Where does this Egypt data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Egypt. Statizoid, drawing on UNAIDS estimates. Retrieved 11 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/egypt-arab-rep/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/egypt-arab-rep/">Access to anti-retroviral drugs, female in Egypt</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.